GleamWall
中文EN

LTRN Lantern Pharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1763950 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY27.2%
TTM EPS YoY17.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-250.6%
ROA-124.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets83.5%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.57M$1.79M$1.72M$2.74M$2.44M$3.07M$3.26M$4.27M
SG&A expense$3.81M$1.72M$1.68M$1.46M$1.91M$1.58M$1.51M$1.63M
Operating income-$5.38M-$3.51M-$3.41M-$4.20M-$4.35M-$4.65M-$4.77M-$5.90M
Net income$696,615-$7.07M-$3.33M-$4.07M-$4.18M-$4.33M-$4.54M-$5.88M
EBITDA-$5.37M-$3.50M-$3.40M-$4.20M-$4.35M-$4.65M-$4.77M-$5.89M
EPS (basic)0.05-0.57-0.30—-0.39-0.40-0.42—
EPS (diluted)-0.37-0.57-0.30—-0.39-0.40-0.42—
Weighted avg. shares (diluted)13.63M12.42M11.25M—10.83M10.78M10.78M—
Balance sheet
Cash & equivalents$7.62M$6.66M$4.92M$4.42M$8.39M$6.06M$6.38M$7.51M
Short-term investments$10,882$701,085$1.41M$5.70M$3.97M$9.84M$13.34M$16.50M
Current assets$8.41M$8.46M$7.06M$10.80M$13.46M$17.20M$20.82M$25.25M
PP&E, net$20,789$24,271$28,022$31,875$35,977$39,524$44,025$47,440
Total assets$8.52M$8.60M$7.22M$11.04M$13.63M$17.42M$21.10M$25.57M
Current liabilities$5.65M$4.32M$3.78M$4.50M$4.04M$4.88M$4.29M$4.33M
Total liabilities$7.11M$11.82M$3.78M$4.50M$4.04M$4.90M$4.32M$4.38M
Shareholders' equity$1.41M-$3.22M$3.45M$6.53M$9.59M$12.52M$16.78M$21.19M
Shares outstanding14.94M12.76M11.25M11.25M11.04M10.78M10.78M10.78M
Cash flow statement
Operating cash flow-$3.34M-$2.94M-$3.77M-$2.79M-$4.57M-$3.94M-$4.38M-$3.97M
Capital expenditure———$1$555$0$1,159$3,083
Free cash flow———-$2.79M-$4.57M-$3.94M-$4.38M-$3.97M
Investing cash flow$672,037$692,250$4.25M-$1.70M$5.93M$3.59M$3.24M$3.45M
Financing cash flow$3.63M——$526,459———$0
Depreciation & amortization$3,482$3,751$3,853$4,103$4,102$4,501$4,574$4,574
Stock-based compensation$229,550——$198,939$143,685$160,626$147,750$204,606

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.